Nov 2023

Meet us at SITC 2023 in San Diego

SITC Annual Meeting 2023: Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers

Click here to Register

Oct 2023

Zumutor Biologics Inc announces collaboration with Enzene Biosciences

Zumutor Biologics Inc announces collaboration with Enzene Biosciences for it’s INABLR™ Antibody discovery platform

Click here to read the Press Release

Oct 2023

Meet us at ESMO 2023 in Madrid

ESMO CONGRESS 2023: Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008–patient transcriptome analysis

Click here to Register

Aug 2023

IND (Investigational New Drug) approval for our lead molecule, ZM008 by the USFDA

Zumutor is excited to share the news of an IND (Investigational New Drug) approval for our lead molecule, ZM008 by the USFDA.

Click here to read the Press Release

Aug 2023

Zumutor Biologics Inc announces FDA clearance of IND application of ZM008

Zumutor Biologics Inc announces FDA clearance of IND application of ZM008, a novel monoclonal antibody drug against multiple solid cancers

Click here to read the Press Release

Feb 2023

Zumutor receives the US patent for its novel biologic ZM008

Zumutor receives the US patent for its novel biologic ZM008

Link to Blog Post

Jan 2023

Attended JPM from 9th Jan 2023 to 12th Jan 2023

Attended JPM from 9th Jan 2023 to 12th Jan 2023

Nov 2022

SITC in Nov 2022

SITC in Nov 2022

View

June 2022

Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application

Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application

Link to Blog Post

June 2022

Abrogation of natural killer cell check point pathway

Abrogation of natural killer cell check point pathway

Link to Blog Post

June 2022

Abstract to the 2022 ASCO Annual Meeting (June 3 - June 7, 2022)
Abrogation of Natural Killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers

April 21-22

Virtual ePoster Presentation at the SITC Tumor Immune Microenvironment: A Holistic Approach Workshop, held April 21-22 at SD
Novel therapeutic antibody targeting LLT1-CD161 interaction results in NK cell activation and immune reactive tumor microenvironment in solid cancers

Dec 2021

Zumutor Biologics Secures $6.2M for a Promising Oncology Molecule

Sep 2020

Zumutor Biologics Announces Receipt of a Grant from The United States - India Science & Technology Endowment Board

Feb 2020

Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors

Jan 2020

Kavitha Iyer Rodrigues, Founder-CEO showcased Zumutor at the Bio Century reception at JPM 38th Annual Conference in San Francisco

Dec 2019

Zumutor Biologics raises $ 4 million in Series A2 funding

Zumutor Biologics raises $ 4 million in Series A2 funding

Link to Blog Post

Nov 2019

Kavitha Iyer Rodrigues, Founder-CEO presented at the National Foundation of Cancer Research Fall Meeting of Oncology Investors Conference on 12th and 13th November 2019 at New York City

Visit

Venue: at 1155 6th Ave, New York City

June 2019

At BIO 2019 on June 6th – we made a presentation on Thursday, June 6th at 11:15AM EST at the Start-up Stadium Booth #3071

Visit

Ramon Valencia, VP- Corporate Development and Strategy was our lead ([email protected])

June 2019

Dr. Sunit Maity, our Director, Process Development was at BIO International at Philly between June 3rd and 6th at the International Pavilion, India Booth #3927

Visit

Dr. Sunit Maity – [email protected] was available for one-on-one meetings

May-June 2019

Our Founder & CEO, Kavitha Iyer Rodrigues and CSO, Dr. Maloy Ghosh were at ASCO, May 31st to 4th June at Chicago

Visit

Maloy Ghosh – [email protected] was available for one-on-one meetings

May 2019

Our Founder & CEO, Ms Kavitha Iyer Rodrigues was at the 5th Annual Immuno-Oncology BD&L and Investment Forum on May 31st in Chicago for Partnering and Investment meetings

May 2019

Our Founder & CEO, Ms Kavitha Iyer Rodrigues was at the Asia Pacific Week 2019 Conference in Berlin between 13th and 19th May 2019

Dec 2018

Kavitha Iyer Rodrigues, CEO receives the “Women Transforming India 2018” award at Delhi on December 16, 2018 from the Vice President of India

Visit

http://www.zumutor.com/2018/12/kavitha-iyer-rodrigues-ceo-receives-the-women-transforming-india-2018-award-at-delhi-on-december-16-2018-from-the-vice-president-of-india/

Nov 2018

Zumutor Biologics Awarded the BioExcellence Emerging Company Award in 2018 by the Karnataka State Government

Visit

http://www.zumutor.com/2018/12/zumutor-biologics-awarded-the-bioexcellence-emerging-company-award-in-2018-by-the-karnataka-state-government/

Nov 2018

Dr. Maloy Ghosh, Chief Scientific Officer at Zumutor Biologics Inc spoke on 'Human Antibody Library Development for therapeutic monoclonal antibody products'at INNO 2018

Visit

http://www.zumutor.com/2018/12/dr-maloy-ghosh-chief-scientific-officer-at-zumutor-biologics-inc-spoke-on-human-antibody-library-development-for-therapeutic-monoclonal-antibody-products-at-inno-2018/

May 2018

Syngene International Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services

Visit

http://zumutor.com/wp-content/uploads/2018/06/Zumutor-Syngene-Press-Release.pdf

Feb 2017

Kavitha Iyer-Rodrigues: Molecular formula to success

Nov 2016

Zumutor was at PEGS Europe, 31st October to 4th November, Lisbon

Nov 2016

Zumutor was at PEGS Europe, 31st October to 4th November, Lisbon

Aug 2016

Catalent Biologics and Zumutor Collaborate to Develop Antibodies with Enhanced ADCC Activity

Aug 2016

Collaboration between Bhami Research and Zumutor Inc

Visit